Login / Signup

Sunitinib for Metastatic Renal Cell Carcinoma: Real-World Data from the STAR-TOR Registry and Detailed Literature Review.

Annemarie UhligLothar BergmannMartin BögemannThomas FischerPeter J GoebellMarianne LeitsmannMathias ReichertMichael RinkKatrin SchlackLutz TrojanJohannes UhligMichael WoikeArne Strauß
Published in: Urologia internationalis (2024)
This study adds further real-world evidence of the persisting relevance of sunitinib for patients with a/mRCC who cannot receive or tolerate immune checkpoint inhibitors. The study population includes a high proportion of patients with unfavorable MSKCC poor-risk score, but shows still good PFS and OS results, while the drug demonstrates a favorable safety profile. The STAR-TOR registry is also registered in the database of US library of medicine (NCT00700258).
Keyphrases
  • metastatic renal cell carcinoma
  • renal cell carcinoma
  • emergency department
  • case report
  • adverse drug
  • big data
  • data analysis